PSOMRI has a targeted drug portfolio against skin inflammation, by combining bioinformatics with biochemical and pharmacokinetic enhancements to enable robust IP. Our lead compound MRI001 is highly potent and well tolerated across multiple preclinical in vivo models using psoriasis as a model for skin-driven inflammation and three-month toxicology studies in rodent and non-rodents. Restoring aberrant signaling from skin cells maximizes effect while circumvents the need of lifelong immunosuppression and associated neoplastic and infectious risks.